XFOR READ THE FULL XFOR RESEARCH REPORT Business Update Full Enrollment of Phase 3 4WARD Trial Expected in 2H25 X4 ...
Triplet therapy with bortezomib, lenalidomide and dexamethasone — a regimen often referred to as VRd — is a current standard ...
Q4 2024 Earnings Call Transcript March 25, 2025 Corvus Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback